Pharma & Medical Device Sales Mortgages

Pharma & medical device sales mortgage from a lender who reads W-2 base + commission, quota accelerator structure, President’s Club bonus, RSU stock compensation, quarterly spiff income, and sign-on/retention bonuses as one income picture.

Working pharmaceutical and medical device sales representatives carry one of the most W-2-dominant qualifying profiles in any sales profession — with substantial RSU stock compensation, President’s Club bonuses, and quota-driven accelerator commission structures that generalist underwriting routinely misclassifies. Per BLS OEWS May 2024 data, sales representatives wholesale & manufacturing technical & scientific products run a median wage of $99,710 with top 10% over $213,460. These numbers substantially understate top-performing pharma and device reps: established pharmaceutical sales representatives at Pfizer (NYSE: PFE), Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), AstraZeneca (NASDAQ: AZN), Novartis (NYSE: NVS), Roche, GlaxoSmithKline, and Sanofi commonly earn $150K–$300K OTE through W-2 base plus commission plus quarterly bonuses plus RSU stock vesting; medical device sales reps at Medtronic (NYSE: MDT), Stryker (NYSE: SYK), Boston Scientific (NYSE: BSX), Zimmer Biomet (NYSE: ZBH), Smith+Nephew, Abbott (NYSE: ABT), Edwards Lifesciences (NYSE: EW), Intuitive Surgical (NASDAQ: ISRG), and Becton Dickinson (NYSE: BDX) commonly $200K–$500K OTE through higher variable comp structures with case-by-case OR operating-room based commission; top performers consistently making President’s Club at either category $400K–$800K+ through accelerator commission past quota plus elevated RSU grants plus retention bonuses; and the elite tier in specialty oncology, surgical implants, robotic surgery (Intuitive Surgical da Vinci, Stryker Mako), and rare disease specialty pharma $600K–$1.5M+ through high-value product complexity. The qualifying mechanic that matters: aggregating W-2 base + commission + quarterly bonus + President’s Club + RSU vesting + retention bonuses under Fannie Mae B3-3.1-01 variable income with 24-month average, plus B3-3.1-09 stock vesting analysis for RSU compensation, produces the actual income picture working reps carry — not the base-salary-only number that generalist underwriters sometimes substitute.

Talk to Our Team See how pharma/device sales qualifying works

Broker NMLS #1072866 · Specialist in W-2 base + commission, quota accelerator structure, President’s Club bonus, RSU stock compensation aggregation, quarterly spiff income, and sign-on/retention bonuses for pharma and medical device sales mortgages

$150K-$800K+

Established working pharma rep ($150K-$300K typical) and medical device rep ($200K-$500K typical) OTE range; top performers consistently making President’s Club $400K-$800K+; elite specialty $600K-$1.5M+

W-2 dominant

Pharma and medical device sales is overwhelmingly W-2 employer-paid commission income, in contrast to realtors, MLOs, and insurance agents who often operate as 1099 Schedule C self-employed

RSU vesting

Substantial RSU stock compensation at publicly-traded pharma and device companies, typically $30K-$200K+ annually vesting for established reps after multi-year retention through long-term incentive plans

President’s Club

Top 10-15% of reps consistently making President’s Club tier qualify for trip, cash bonus, elevated RSU grant, and accelerator commission past quota — the elite income tier marker

Stairway Mortgage qualifies working pharmaceutical and medical device sales representatives on the full income picture — W-2 base salary plus quarterly commission tied to quota attainment plus accelerator commission past 100% quota plus annual President’s Club bonus for top performers (typically 10-15% of reps qualify) plus quarterly spiff income from short-term promotional sales contests plus RSU stock compensation vesting on multi-year schedules from long-term incentive plans (LTIP) at publicly-traded employers including Pfizer, Merck, Johnson & Johnson, Bristol Myers Squibb, AbbVie, Eli Lilly, AstraZeneca, Novartis, Roche, GlaxoSmithKline, Sanofi, Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Smith+Nephew, Abbott, Edwards Lifesciences, Intuitive Surgical, and Becton Dickinson plus sign-on bonuses for newly recruited reps plus retention bonuses for proven performers in competitive territories plus auto allowance and vehicle/fuel programs (typically $9K-$15K annually) plus district/regional sales manager override income for reps promoted to management plus strategic account manager bonuses for reps managing key hospital, IDN (Integrated Delivery Network), or GPO (Group Purchasing Organization) relationships, all under Fannie Mae B3-3.1-01 variable income with 24-month average plus B3-3.1-09 for RSU vesting analysis. A new pharma rep in years 1-2 building territory, an established pharma rep with primary care or specialty product responsibility, an established medical device rep with case-by-case OR-based commission, a top-performing President’s Club consistent rep with elevated RSU grants, and a district/regional sales manager combining personal management override with team performance bonus each get qualified using methods that fit their actual structure. This is the first sales sub-page where W-2 income is dominant rather than 1099 Schedule C — reflecting the employer-paid commission structure that distinguishes pharma and device sales from real estate, mortgage, insurance, and securities sales professions covered elsewhere in the Sales Professionals hub. Or skip ahead: browse every loan program, run numbers on 100+ mortgage calculators, or check today's rates. For the parent hub and other sales professional paths, see our sales professionals mortgage hub.

01 · Pharma/device sales mortgage at a glance

Key facts every pharma or medical device sales rep should know before applying for a mortgage.

W-2 dominant

Pharma and medical device sales is overwhelmingly W-2 employer-paid commission income, qualifying under Fannie Mae B3-3.1-01 as variable income with 24-month average. This contrasts sharply with realtors, MLOs, and insurance agents who often operate as 1099 Schedule C self-employed. The W-2 dominance simplifies the qualifying mechanic but requires proper documentation of all variable components.

RSU equity

RSU stock compensation from long-term incentive plans (LTIP) at publicly-traded employers is a substantial income component for established reps. RSU vesting income qualifies under Fannie Mae B3-3.1-09 with vesting schedule documentation. For tenured reps at major pharma or device companies, RSU vesting commonly adds $30K-$200K+ annually.

Quota accelerators

Pharma and device sales commission structures use quota-based accelerator mechanics: commission rate increases past 100% of quota (typically to 150-200% of base commission rate) and may accelerate further past 110-120% quota. President’s Club tier (typically top 10-15% of reps) receives accelerated commission plus annual trip, cash bonus, and elevated RSU grant.

Open Payments

CMS Open Payments transparency reporting under the Physician Payments Sunshine Act (Section 6002 of the Affordable Care Act) requires manufacturers to report payments to physicians and teaching hospitals. This regulatory framework doesn’t affect mortgage qualifying directly but provides context for the pharma/device industry sales environment.

02 · Where you are in your pharma/device sales career

Pharma & medical device sales mortgage solutions for every career stage.

Each stage of a pharma or medical device sales career has its own qualifying logic. A new rep in years 1-2 building territory has a different mortgage path than an established pharma rep, an established medical device rep with case-based commission, a top performer consistently making President’s Club, or a district/regional manager combining personal management override with team performance bonus.

New rep (Years 1–2)

"Recently hired pharma or device rep at established manufacturer (Pfizer, Merck, J&J, AbbVie, Lilly, Medtronic, Stryker, Boston Scientific) with W-2 base + ramping commission. Limited 24-month variable income history."

Annual income $90K–$140K W-2 base + ramping commission
Sign-on bonus typically $10K-$30K plus relocation
RSU vesting just beginning if any LTIP grants
Conventional with W-2 documentation

See new-rep mechanics

Established pharma rep

"Established pharmaceutical sales rep at Pfizer, Merck, J&J Pharma, Bristol Myers Squibb, AbbVie, Lilly, AstraZeneca, Novartis, Roche, GSK, or Sanofi with consistent 2-year+ territory performance. Primary care or specialty product responsibility."

Annual income $150K–$300K W-2 base + commission + bonus
2-year+ variable income history supports B3-3.1-01
RSU vesting $25K-$80K annually from LTIP grants
Conventional Conforming or Jumbo

See established pharma mechanics

Established medical device rep

"Established medical device sales rep at Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Smith+Nephew, Abbott, Edwards Lifesciences, Intuitive Surgical, or Becton Dickinson. Case-by-case or OR-based commission structure with higher variable comp."

Annual income $200K–$500K W-2 base + commission + bonus
Case-based or OR-based commission with higher variable %
RSU vesting $40K-$150K annually from LTIP grants
Conventional Jumbo typical

See established device mechanics

Top performer / President’s Club consistent

"Top performer consistently making President’s Club tier (top 10-15% of reps). Accelerator commission past quota, elevated RSU grants, additional retention bonuses, possibly transitioning to strategic account or training roles."

Annual income $400K–$800K+ across all components
Accelerator commission past 100-120% quota
Elevated RSU grants $100K-$300K+ annually from LTIP
Multi-source W-2 + RSU + retention bonus aggregation

See top performer mechanics

District/Regional sales manager

"District or regional sales manager promoted from individual contributor rep role. Combines personal management override on team production with team performance bonus, plus continuing RSU vesting from LTIP grants and elevated management-tier grants."

Annual income $250K–$600K W-2 base + override + bonus + RSU
Team production override structure
Elevated management-tier RSU grants
Conventional Jumbo with multi-component W-2 documentation

See manager mechanics

03 · The qualification mechanics

How we calculate qualifying income for your pharma or medical device sales mortgage.

Four methods cover almost every pharma and medical device rep file we’ve closed. The right method depends on your career stage, whether you specialize in pharma vs medical device sales, your RSU stock compensation tier, and whether you have transitioned to district or regional sales management.

Method 1 — W-2 base + commission + quarterly bonus + President’s Club (the rep default)

The dominant pattern for working pharma and medical device sales reps. Under Fannie Mae B3-3.1-01, W-2 base salary plus quarterly commission tied to quota attainment plus quarterly bonus plus annual President’s Club bonus (for top performers) qualifies as variable income with 24-month average. Quota structures typically pay base commission at 100% quota with accelerator commission rates of 150-200% past 100% quota, sometimes additional acceleration past 110-120% quota. President’s Club bonus (typically 10-15% of reps qualify) includes additional cash bonus, trip valued at $5K-$10K, and elevated RSU grant for the following year. All components aggregate into qualifying variable income.

Method 2 — W-2 + RSU stock compensation aggregation (the high-tier method)

For established reps with substantial RSU stock compensation from long-term incentive plan (LTIP) grants. RSU compensation qualifies under Fannie Mae B3-3.1-09 as other source of income with vesting schedule documentation showing continuing vesting through at least 3 years post-application. RSU grant value depends on rep tier (typical individual contributor RSU grants $20K-$60K annually) plus elevated grants for President’s Club qualifiers and management tier reps. RSU vesting income aggregates with base W-2 + commission + bonuses under combined B3-3.1-01 + B3-3.1-09 analysis. For tenured top performers at major pharma or device companies, RSU vesting commonly adds $80K-$200K+ to annual qualifying income.

Method 3 — Multi-year sign-on / retention bonus structures (the transition method)

For reps with active sign-on bonus structures from recent hiring or retention bonus programs for proven performers in competitive territories. Sign-on bonuses typically structured as $10K-$50K paid at hire plus additional payments at 12-month and 24-month anniversaries to support retention. Retention bonuses for established reps typically $25K-$100K+ paid as multi-year vesting incentive to retain key territory performance. Under B3-3.1-01, multi-year bonus structures with documented vesting schedules and continuing employment requirements qualify as continuing variable income with proper employer documentation. The compensation letter from HR documenting the bonus schedule supports the qualifying analysis.

Method 4 — District/regional sales manager (multi-component W-2)

For reps promoted to district or regional sales management roles combining personal compensation with team production override. Under B3-3.1-01, manager W-2 income includes elevated base salary (typically $140K-$220K for district managers, $200K-$320K for regional managers), management override commission on team production (typically 5-15% of team aggregate commission), management performance bonus tied to team quota attainment, and elevated RSU grants from management-tier LTIP. The multi-component management W-2 commonly aggregates $250K-$600K+ with proper documentation of each component through HR compensation letter. IRC Section 3401 wage definitions apply to all W-2 components.

04 · What generalist underwriting misses

The income most lenders refuse to count on a pharma or medical device sales file.

Six income facts that show up consistently on working pharma and medical device sales rep files and that generalist lenders typically either ignore, mis-categorize, or refuse to apply correctly. Each one is documentable; the lender just has to read the pharma/device W-2 multi-component pattern properly.

Quota-based accelerator commission structure

Pharma and device sales commission structures use quota-based accelerator mechanics: base commission rate to 100% quota, then accelerator commission rate (typically 150-200% of base) past 100% quota, sometimes further acceleration past 110-120% quota. For a rep at 130% of quota, accelerator commission commonly produces 30-50% of total commission income. Under B3-3.1-01, accelerator commission qualifies as continuing variable income with 2-year history. Generalist underwriters sometimes don’t understand the accelerator mechanic and undercount commission income.

President’s Club bonus (top 10-15% of reps)

President’s Club tier qualification (typically top 10-15% of reps based on quota attainment, growth, and product mix) brings annual cash bonus ($15K-$50K typical), recognition trip valued at $5K-$10K, and elevated RSU grant for the following fiscal year. President’s Club consistent reps (multi-year qualifiers) carry the bonus as continuing variable income under B3-3.1-01 with multi-year history documenting the bonus continuity. Generalist underwriters often classify as "discretionary not stable" without doing the documentation work.

RSU stock compensation from LTIP grants

RSU stock compensation from long-term incentive plans (LTIP) at publicly-traded employers (Pfizer, Merck, J&J, BMS, AbbVie, Lilly, AstraZeneca, Novartis, Roche, GSK, Sanofi, Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Abbott, Edwards Lifesciences, Intuitive Surgical, BD) qualifies under B3-3.1-09 as other source of income with vesting schedule documentation. For established reps, RSU vesting commonly $30K-$200K+ annually. For top performers and managers, RSU can exceed $200K. Generalist underwriters often refuse RSU vesting income or substantially discount it as "speculative future stock price."

Quarterly spiff and SPIF promotional bonuses

Quarterly spiff (Sales Performance Incentive Funds) bonuses for short-term promotional sales contests are common in pharma and device sales, typically $1K-$5K per qualifying contest with multiple contests per quarter. For active reps consistently winning quarterly spiff contests, annual spiff income commonly $8K-$25K supplementing base commission. Under B3-3.1-01, recurring spiff income qualifies as continuing variable income with 2-year history when documented through HR records and W-2 detail.

Auto allowance and vehicle/fuel programs

Pharma and device reps typically receive auto allowance, company vehicle, or vehicle reimbursement program valued at $9K-$15K annually depending on employer. The auto component flows through W-2 as additional taxable income (vehicle allowance) or as non-taxable reimbursement (mileage). For mortgage qualifying purposes, the taxable auto allowance component aggregates into W-2 income; the non-taxable reimbursement provides cost offset for the rep’s personal vehicle expense. Reduces effective cost of ownership for the rep’s personal vehicle and improves debt-to-income calculation.

Sign-on and retention bonus structures with vesting

Sign-on bonuses for newly recruited reps (typically $10K-$50K paid in installments over 12-24 months with vesting) and retention bonuses for proven performers (typically $25K-$100K+ as multi-year vesting incentive) are common in pharma and device sales. Under B3-3.1-01, multi-year bonus structures with documented vesting schedules and continuing employment requirements qualify as continuing variable income with proper HR compensation letter documenting the bonus schedule.

05 · Match the program to your pharma/device sales situation

Which loan program fits your pharma or medical device sales mortgage situation.

Seven loan-program categories cover essentially every pharma and medical device sales file we’ve closed. The mix tilts heavily toward Conventional Conforming and Jumbo with rigorous B3-3.1-01 W-2 multi-component aggregation plus B3-3.1-09 RSU vesting analysis. Bank Statement Non-QM is rare since pharma/device sales is overwhelmingly W-2.

Conventional Conforming W-2 (primary)

Established pharma or device reps with 2-year W-2 history
B3-3.1-01 variable income with 24-month average
Loan limits to $766,550 (FL) 2024-25

Best for: Established W-2 rep

Conventional Jumbo (top performer)

Top performers and managers at $300K+ income
Multi-source W-2 + RSU + bonus aggregation
Loan amounts above conforming limits to $2M+

Best for: President’s Club consistent rep

Conventional Jumbo + RSU equity

Tenured reps with substantial RSU vesting from LTIP
B3-3.1-09 RSU vesting analysis aggregated with W-2
3+ year vesting schedule documentation

Best for: Tenured rep with stock

Multi-source (W-2 + RSU + bonus)

Top performers with complex multi-component income
Aggregates base + commission + bonus + RSU + retention
Conventional Jumbo with full HR compensation letter

Best for: Multi-component top rep

Asset-Depletion Non-QM (post-IPO/stock liquidity)

Reps with significant post-vesting liquid stock holdings
Liquid assets amortized over 360 months as implied income
Useful when stock liquidity exceeds W-2 income tier

Best for: Stock-rich rep

Bank Statement Program Non-QM (rare)

Reps with side 1099 consulting income (uncommon)
12 or 24 months of business bank statements
0.75-1.5% rate premium — rare for W-2-dominant reps

Best for: Rare 1099-side rep

FHA Conventional Alternative

New reps in years 1-2 with limited W-2 history
3.5% down minimum, gift funds liberally accepted
MIP cost — alternative when conventional history thin

Best for: New rep w/ co-borrower

06 · Why this mortgage requires specialty expertise

The pharma/device sales mortgage in context: 6 forces shaping how reps qualify.

Pharma and medical device sales mortgage qualifying sits at the intersection of pharma industry consolidation and biosimilar competition, the IRA drug pricing reform, the GLP-1 boom (Ozempic, Wegovy, Mounjaro, Zepbound) reshaping pharma sales territories, medical device consolidation through M&A activity, hospital and IDN consolidation affecting buyer power, and robotic surgery growth at Intuitive Surgical and Stryker Mako. Each force shapes what a working rep’s qualifying picture looks like.

Force 1 — Pharma industry consolidation and biosimilar competition

The pharmaceutical industry has consolidated substantially over the past decade through mega-mergers (Pfizer/Wyeth, AbbVie/Allergan, Bristol Myers Squibb/Celgene, Merck/Cubist, AstraZeneca/Alexion, Pfizer/Seagen, AbbVie/ImmunoGen) and smaller deals. Concurrently, biosimilar competition has emerged for major branded biologics (Humira biosimilars launching 2023; Stelara, Eylea biosimilars in development), reshaping commission territories for affected reps. The mortgage implication: pharma rep territory and product responsibility can shift through M&A integration, requiring documentation of continuity in the new combined organization. We coordinate with HR documentation showing the post-merger reporting structure and quota assignment.

Force 2 — IRA drug pricing reform (2022)

The Inflation Reduction Act of 2022 included Medicare drug pricing negotiation provisions affecting major branded drugs starting 2026 (first negotiation list announced 2023 covering Eliquis, Xarelto, Januvia, Jardiance, Enbrel, Imbruvica, Farxiga, Entresto, Stelara, Fiasp/NovoLog). The negotiation framework affects pricing for these drugs and others added in subsequent years, with potential downstream effects on manufacturer revenue and rep commission structures. The mortgage implication: pharma reps in affected therapeutic areas may see commission structure modifications — we document current compensation framework and any anticipated changes.

Force 3 — GLP-1 boom reshaping pharma sales territories

The GLP-1 (glucagon-like peptide-1) receptor agonist boom — Eli Lilly’s Mounjaro (tirzepatide) and Zepbound (tirzepatide for obesity), Novo Nordisk’s Ozempic (semaglutide) and Wegovy (semaglutide for obesity) — has reshaped pharma sales territories at affected companies. Lilly and Novo Nordisk reps in diabetes and obesity therapeutic areas have seen substantial production volume increases driven by the GLP-1 launch trajectory. The mortgage implication: reps in GLP-1 territories may have substantially higher recent income vs prior 24-month average, requiring documentation of the production sustainability through HR compensation letter showing continuing quota and territory assignment.

Force 4 — Medical device consolidation through M&A

Medical device industry consolidation has continued through significant M&A activity: Johnson & Johnson MedTech’s acquisition of Auris Health (robotic surgery), Abiomed (cardiology), and Shockwave Medical (intravascular lithotripsy); Stryker’s Mako Surgical acquisition driving robotic orthopedic surgery growth; Boston Scientific’s acquisitions including Axonics and Apollo Endosurgery; Medtronic’s ongoing portfolio activity. The mortgage implication: medical device reps may experience territory and product responsibility changes through M&A integration affecting commission structure during transition periods. We document continuity through the acquirer’s HR.

Force 5 — Hospital and IDN consolidation

The U.S. hospital industry continues to consolidate through health system M&A activity (HCA Healthcare, Ascension, Advocate Health, AdventHealth, Atrium Health, Common Spirit Health, Tenet Healthcare, and others) and IDN (Integrated Delivery Network) expansion. GPO (Group Purchasing Organization) consolidation (Vizient, Premier, HealthTrust) further centralizes hospital purchasing decisions. The mortgage implication: medical device reps managing strategic account relationships with consolidated health systems carry account complexity affecting commission income patterns. Strategic account manager roles command elevated comp tier.

Force 6 — Robotic surgery growth (Intuitive Surgical, Stryker Mako)

Robotic surgery has been a sustained growth segment within medical device sales. Intuitive Surgical (NASDAQ: ISRG) with the da Vinci surgical system has been the dominant robotic surgery platform with substantial procedure growth across general surgery, urology, gynecology, and other specialties. Stryker’s Mako platform has driven robotic orthopedic surgery growth in knee and hip replacement procedures. The mortgage implication: medical device reps in robotic surgery territories at Intuitive Surgical or Stryker Mako commonly carry elevated income tier reflecting platform value and procedure complexity. Top robotic surgery reps consistently $500K-$1M+ OTE.

07 · The mortgage shifts as your pharma/device sales career develops

Pharma & medical device sales mortgage by career stage.

A timeline view of how the right mortgage program changes as you progress from new rep through established producer to top performer or district/regional manager with elevated RSU compensation tier.

Years 1–2

New rep

Comp profile: $90K–$140K W-2 base + ramping commission + sign-on bonus typically $10K-$30K. Limited 24-month variable income history. Dominant qualifying method: Conventional with W-2 documentation; sign-on bonus structure documented through HR. Common purchase: $400K–$600K primary residence. Watch-out: Ramping commission means current quarterly income exceeds 24-month average; underwriter focuses on the 2-year average per B3-3.1-01.

Years 3–7

Established pharma or medical device rep

Comp profile: $150K–$500K W-2 across base + commission + bonus depending on pharma ($150K-$300K typical) vs medical device ($200K-$500K typical) plus RSU vesting from LTIP. Dominant qualifying method: Conventional Conforming or Jumbo with B3-3.1-01 W-2 variable income plus B3-3.1-09 RSU vesting analysis. Common purchase: $600K–$1.2M primary residence. Watch-out: RSU vesting income must be documented through 3+ year continuing vesting schedule for proper qualifying treatment.

Top performer

Top performer / President’s Club consistent

Comp profile: $400K–$800K+ across W-2 base + accelerator commission past quota + President’s Club bonus + elevated RSU grants + possible retention bonus. Dominant qualifying method: Conventional Jumbo with multi-source W-2 + RSU + bonus aggregation. Common purchase: $1M–$1.8M primary residence. Watch-out: Multi-year President’s Club qualification supports continuing bonus narrative; single-year qualification gets discounted as "achievement-based variable."

Manager / SAM

District/regional manager or strategic account manager

Comp profile: $250K–$1M+ across elevated management base + team production override + management performance bonus + elevated management-tier RSU + strategic account bonuses if SAM role. Dominant qualifying method: Conventional Jumbo with multi-component W-2 documentation. Common purchase: $1M–$2.5M primary residence. Watch-out: Management override structure requires HR documentation of the team production override methodology and multi-year continuity.

08 · What pharma and device reps say

What pharma and medical device sales reps say about their Stairway mortgage.

Names abbreviated for client privacy. Employer details anonymized. Numbers are real.

"Established pharmaceutical sales rep at a major branded manufacturer for 7 years. W-2 base salary $115K plus quarterly commission $58K plus annual President’s Club bonus $32K (qualified 5 of 7 years based on quota attainment, growth, and product mix) plus RSU vesting from LTIP grants $48K annually (multi-year vesting schedule from grants over the past 5 years). Plus auto allowance $11K. Total W-2 averaging $264K over the 2-year period. The first lender pulled my W-2 and applied conventional 24-month average treatment, but they then treated the President’s Club bonus as ‘discretionary not stable’ despite 5-year qualification history, refused the RSU vesting income entirely as ‘future stock speculation,’ and offered me $585K based on $185K qualifying. Jim’s team documented the President’s Club bonus history with HR compensation letter showing 5-year qualification continuity, ran B3-3.1-09 RSU vesting analysis with vesting schedule documentation showing 4-year forward continuing vest from existing LTIP grants, and qualified me on the consolidated picture. $885K close Conventional Jumbo on a Coral Springs home in 38 days."

Rachel D.

Established pharma rep · Coral Springs

"Top-performing medical device sales rep in robotic surgery for 6 years at a publicly-traded device manufacturer. W-2 base salary $145K plus case-by-case OR commission $235K (case-based commission structure with accelerator past 100% quota) plus quarterly spiff bonuses $18K plus annual President’s Club bonus $42K (qualified 4 of 6 years) plus retention bonus $35K (multi-year vesting incentive structure for proven territory performance) plus RSU vesting from LTIP $95K annually. Plus auto allowance $13K. Total W-2 averaging $583K over the 2-year period. The first lender saw the multiple W-2 components, called the case-by-case commission ‘variable not stable for jumbo qualifying,’ refused the retention bonus as ‘non-continuing one-time,’ refused the RSU vesting income, and offered me $785K based on base + standard commission. Jim’s team documented the OR-based commission structure with HR compensation letter showing 6-year continuous case-based comp methodology, documented the retention bonus multi-year vesting schedule, ran B3-3.1-09 RSU vesting analysis with 4-year continuing vest documentation, and qualified me on the consolidated multi-source picture. $1.45M close Conventional Jumbo on a Weston home in 44 days."

Anthony M.

Robotic surgery device rep · Weston

"District sales manager for 4 years at a major medical device manufacturer, promoted from individual contributor rep role after 6 years. W-2 base salary $185K plus management override on team production $145K (covering 8% override on 6 reps in the district producing approximately $1.8M aggregate annual commission) plus management performance bonus $52K (tied to district quota attainment) plus elevated management-tier RSU vesting from LTIP $125K annually plus retention bonus $40K (multi-year vesting incentive). Total W-2 averaging $547K over the 2-year period. The first lender saw the management override structure, called it ‘dependent on team retention not stable,’ treated the elevated management RSU as ‘future stock speculation,’ and offered me $885K based on management base + performance bonus alone. Jim’s team documented the management override methodology with HR compensation letter showing the 8% override structure and 4-year continuous management role history, the elevated management-tier RSU vesting under B3-3.1-09 with vesting schedule documentation showing continuing vest through 5 years from existing grants, and qualified me on the consolidated picture. $1.35M close Conventional Jumbo on a Plantation home in 39 days."

Catherine L.

District sales manager · Plantation

09 · Pharma/device sales mortgage FAQs

Pharma and medical device sales mortgage questions, answered.

More pharma and device sales mortgage resources at Stairway

My base salary is only $115K but my total W-2 with commission and bonus is $260K+. Does that count for qualifying?

Yes — total W-2 variable income including base + commission + bonus qualifies under Fannie Mae B3-3.1-01 with 24-month average. The qualifying income is the 2-year average of total W-2 not just base salary. We document each component (base, quarterly commission, President’s Club bonus, spiff bonuses) through HR compensation letter to support the variable income treatment.

My RSU vesting is substantial. How does that count toward qualifying?

RSU stock compensation from long-term incentive plan (LTIP) grants qualifies under Fannie Mae B3-3.1-09 as other source of income with vesting schedule documentation showing continuing vesting through at least 3 years post-application. We document the RSU grant history, vesting schedule, and projected continuing vest from existing grants. For tenured reps, RSU vesting commonly adds $30K-$200K+ to annual qualifying income.

I’ve made President’s Club 4 of the past 5 years. Does that count as continuing income?

Yes — multi-year President’s Club qualification (top 10-15% of reps) supports continuing variable income treatment under B3-3.1-01. We document the qualification history with HR compensation letter showing the multi-year continuity. Single-year President’s Club gets discounted as "achievement-based variable"; multi-year qualifies as continuing bonus.

My commission structure has accelerators past 100% quota. How does the underwriter understand that?

Pharma and device commission structures use quota-based accelerator mechanics where commission rate increases past 100% quota (typically to 150-200% of base commission rate) and may accelerate further past 110-120% quota. Under B3-3.1-01, accelerator commission income qualifies as continuing variable income with 2-year history. We document the accelerator mechanic with HR compensation letter and W-2 detail.

I received a sign-on bonus 18 months ago with installments still to come. Does that count?

Active sign-on bonus structures with documented vesting schedules and continuing employment requirements qualify as continuing variable income under B3-3.1-01. We document the bonus schedule with HR compensation letter showing remaining installments and continuing employment requirement. The bonus income aggregates into qualifying picture during the active payment period.

What documentation do I need for a pharma or medical device sales mortgage?

Typically: two complete federal 1040s with all schedules; two complete W-2s showing base + commission + bonus + other variable components; current pay stubs covering 30 days; HR compensation letter documenting commission structure, quota mechanics, President’s Club qualification history, and RSU grant history; LTIP grant documentation showing vesting schedule for existing RSU grants; 60 days of personal bank statements; any retention bonus or sign-on bonus letters with vesting schedules.

My quarterly commission varies substantially by territory performance. How does 24-month averaging treat that?

Under B3-3.1-01, the 24-month average smooths quarter-to-quarter variation in commission. For reps with strong overall 2-year performance and quarterly variation, the 24-month average produces a representative qualifying number. For reps with declining trend or substantial recent compression, underwriters apply discounted treatment to reflect the trend. We evaluate strategic timing relative to recent performance pattern.

I’m a Lilly diabetes rep in a GLP-1 territory. My 2024 income was much higher than 2023. Will the average hurt me?

Possibly — the 24-month average between strong 2024 and weaker 2023 produces a number below current capacity. Strategic options: (1) wait for higher 2025 quarterly performance to come into the rolling 24-month window, which improves the average; (2) document the post-GLP-1-launch territory expansion through HR compensation letter showing continuing quota and territory assignment supporting current performance as sustainable; (3) evaluate Asset-Depletion Non-QM if liquid reserves are substantial. We model the options.

My company was acquired by another pharma. How does that affect qualifying?

Pharma industry M&A activity is common and underwriting handles it routinely. We document the acquisition through HR letter confirming continuing employment in the acquirer entity, the post-acquisition territory and quota assignment, and the compensation structure continuity. If commission structure changed materially through the acquisition, we document the new structure and provide pro-forma analysis. Recent merger activity affecting reps includes Pfizer/Seagen, BMS/Karuna, Merck/Prometheus, and others.

Are mortgage rates higher for pharma or medical device reps?

No — mortgage rates for pharma and device reps are the same as for any other borrower at the same credit profile and loan amount. The W-2-dominant income structure with proper documentation produces strong Conventional Conforming and Jumbo outcomes at standard pricing.

My RSU grants vest over 4 years. Can I count vesting that comes after my mortgage close?

Yes — future RSU vesting from existing grants qualifies under B3-3.1-09 with vesting schedule documentation showing continuing vest through at least 3 years post-application. We document the existing grants with grant agreements and vesting schedules. RSU vesting income calculated from documented existing grants (not speculative future grants) qualifies as continuing income.

I’m a strategic account manager for major IDN customers. How does that comp structure work?

Strategic account manager (SAM) roles in medical device sales typically combine elevated base salary with strategic account performance bonuses tied to large IDN, GPO, or health system customer relationships. Under B3-3.1-01, the multi-component SAM W-2 qualifies as variable income with 24-month average. We document the SAM structure with HR compensation letter showing the account assignment and performance metrics.

My spouse is also in pharma/device sales. How does that affect us?

Two-rep households produce strong joint qualifying when both spouses have established 2-year W-2 histories. Both files combine as co-borrowers with full B3-3.1-01 analysis on each W-2 plus B3-3.1-09 RSU vesting on each LTIP grant history. Combined household income from two established pharma/device reps commonly $400K-$1M+ supports $1M-$2M+ qualifying. Two-RSU households also benefit from combined vesting income aggregation.

I got a substantial retention bonus to stay in my territory. How does that count?

Retention bonus structures with multi-year vesting tied to continuing employment qualify under B3-3.1-01 as continuing variable income during the active vesting period. We document the bonus schedule with HR letter showing remaining installments and continuing employment requirements. Generalist underwriters sometimes refuse retention bonus as "one-time non-continuing" — the vesting schedule documentation supports continuing treatment.

Can I exercise my vested stock to use for down payment?

Yes — vested stock can be sold and used for down payment through normal asset documentation. We document the source of funds as stock sale proceeds with brokerage statements showing the sale transaction. Tax implications (typically short-term or long-term capital gains depending on holding period from vest date) should be reviewed with your CPA. Stock sale proceeds for down payment are common and well-understood by underwriting.

My company offers Employee Stock Purchase Plan (ESPP). Does that count?

ESPP participation provides discount on company stock purchase through payroll deduction (typically 15% discount with 6-month or 12-month offering periods). ESPP shares acquired through the plan represent a source of additional stock holdings on the balance sheet but are not typically aggregated into qualifying income separately from base W-2. The post-tax ESPP contributions reduce take-home pay but build stock asset position over time.

Why do generalist lenders sometimes refuse pharma/device sales files?

Five reasons: (1) using W-2 base salary alone instead of total variable W-2 with proper B3-3.1-01 24-month average; (2) President’s Club bonus classified as "discretionary not stable" without multi-year qualification documentation; (3) RSU vesting refused entirely as "speculative future stock" instead of properly aggregated under B3-3.1-09 with vesting schedule; (4) retention bonus treated as "one-time non-continuing" rather than multi-year vesting; (5) accelerator commission structure mis-modeled or undercounted. The income is all there and verifiable — the file just needs a broker who reads pharma/device W-2 multi-component structure correctly.

My territory was reorganized through company restructuring. How does that affect qualifying?

Territory reorganizations are common in pharma and device sales. We document the new territory assignment through HR letter showing continuing employment, post-reorg quota and product responsibility, and any compensation structure changes. If the new territory has different commission characteristics, we provide pro-forma analysis. The continuing W-2 employment continuity supports qualifying through B3-3.1-01.

I’m considering transitioning from pharma to medical device sales. How should I time my mortgage?

Channel transitions between pharma and device sales create new-employment underwriting where the prior pharma W-2 history supports continuing employment in the same broad profession but the device employer would need to be established. Strategic options: (1) close mortgage in current pharma role BEFORE the transition (uses established 2-year W-2 history); (2) wait 12-24 months post-device-transition to establish the new-employer 2-year history; (3) co-borrower file with spouse W-2 providing stability during transition. We model the options.

My medical device company is private (not publicly traded). Does that change RSU treatment?

Private company equity (RSU, stock options, profits interests) requires different documentation than public company RSU. Private equity grants typically have less liquid market value, more complex vesting and exercise structures, and limited liquidity events. For private company device reps, we coordinate documentation of the grant structure and any recent secondary or tender offer transactions providing valuation comparables. Pre-IPO device companies in late-stage growth (potential IPO candidates) may have substantial paper equity value.

Are there mortgage programs specifically designed for pharma/device reps?

No specialty pharma-or-device-specific products are widely available. What matters is finding a broker who understands W-2-dominant variable income with proper multi-component aggregation: B3-3.1-01 base + commission + accelerator + bonus + spiff, B3-3.1-09 RSU vesting analysis with continuing schedule, and multi-year qualification documentation for President’s Club, retention, and sign-on bonus structures. Conventional Conforming and Jumbo done right produces strong outcomes.

My auto allowance is $11K. Does that count toward qualifying?

Auto allowance flows through W-2 as additional taxable income and aggregates into the total W-2 variable income for B3-3.1-01 24-month average treatment. Non-taxable mileage reimbursement (separate from auto allowance) doesn’t flow through W-2 but reduces personal vehicle cost. We document the auto allowance through W-2 detail.

Can I use Asset-Depletion to qualify on substantial stock holdings?

Yes — for reps with significant post-vesting liquid stock holdings, Asset-Depletion Non-QM qualifies on liquid assets amortized over 360 months as implied income. Useful for tenured reps with $500K-$2M+ of liquid stock holdings (post-vest, freely tradeable shares) where the implied asset-depletion income exceeds W-2 income tier. Pricing carries 0.5-1% rate premium vs Conventional. We model Asset-Depletion alongside conventional B3-3.1-01 + B3-3.1-09 to identify optimal path.

When should I start the mortgage conversation relative to a home purchase?

Ideally 90-120 days before you intend to make an offer. Pharma and device sales files benefit from runway because of multi-component W-2 aggregation, RSU vesting analysis requiring grant documentation, President’s Club bonus continuity documentation, retention or sign-on bonus vesting analysis, and possible coordination with HR for compensation letter documentation. For reps with substantial RSU vesting, additional runway helps document the vesting schedule through brokerage and HR records.

What HR compensation letter should I request from my employer for mortgage qualifying?

Request HR compensation letter covering: base salary, commission calculation methodology (quota structure with accelerator mechanics), 24-month commission history, President’s Club qualification criteria and history, quarterly bonus/spiff structure, RSU grant history with vesting schedules, retention or sign-on bonus structure with remaining vesting, auto allowance details, and current employment status with continuing employment verification. The comprehensive HR letter supports proper B3-3.1-01 + B3-3.1-09 underwriting analysis.

10 · Companion guides & calculators

More on pharma/device sales mortgages, W-2 multi-component aggregation, and RSU vesting analysis.

Other sales paths

Loan-program details

Calculators & tools

11 · Sources & further reading

Sources & further reading.

PhRMA / AdvaMed & pharma/device industry

IRS & tax guidance

Cornell Law — statutory references

Mortgage program & underwriting guidelines

BLS & legislation

12 · What "right door first" looks like

Pharma/device sales mortgage, structured right.

Top-performing medical device sales rep in robotic surgery for 6 years at a publicly-traded device manufacturer with substantial year-over-year procedure volume growth in robotic-assisted surgical procedures. W-2 base salary $145K plus case-by-case OR-based commission of $235K (case-based commission structure with accelerator past 100% quota across approximately 280 robotic surgery cases supported in the territory) plus quarterly spiff bonuses of $18K (winning multiple short-term promotional contests across the year) plus annual President’s Club bonus of $42K (qualified 4 of the past 6 years based on quota attainment, growth, and case complexity metrics) plus retention bonus of $35K (active multi-year vesting incentive structure for proven territory performance in the high-value robotic surgery specialty) plus RSU vesting from LTIP grants of $95K annually (multi-year vesting schedule from LTIP grants over the past 4 years with elevated grants from President’s Club qualification years) plus auto allowance of $13K. Total W-2 averaging $583K over the 2-year period. The first lender saw the multiple W-2 components on the rep’s tax returns and W-2 detail, called the case-by-case OR-based commission "variable not stable for jumbo qualifying" despite 6-year continuous case-based comp methodology, refused the retention bonus as "non-continuing one-time" despite the active multi-year vesting schedule with remaining installments, refused the RSU vesting income entirely as "future stock speculation," and offered the rep $785K Conventional Conforming based on base salary plus standard commission only. They missed that the case-based OR commission is the standard structure for medical device reps in robotic surgery, that retention bonuses with documented multi-year vesting schedules qualify as continuing variable income under B3-3.1-01, and that RSU vesting from existing LTIP grants with documented vesting schedules qualifies under B3-3.1-09 as continuing other income. We pulled the two complete W-2s showing the full base + commission + spiff + bonus components, the HR compensation letter from the device manufacturer documenting the case-based OR commission methodology with 6-year continuous structure plus the retention bonus vesting schedule with remaining installments and continuing employment requirements, the LTIP grant agreements documenting the RSU grant history across 4 years with vesting schedules showing continuing vest through the next 4 years from existing grants, and the personal pay stubs covering the most recent 30 days. Ran the W-2 variable income components (base + case-based commission + spiff + President’s Club + retention bonus) under Fannie Mae B3-3.1-01 with 24-month average plus aggregated the RSU vesting income under B3-3.1-09 with vesting schedule documentation showing 4-year continuing vest. Total qualifying income: approximately $548K. Approved at $1.45M Conventional Jumbo for a Weston home in 44 days. Multi-source pharma/device rep W-2 income with case-based commission + retention bonus + RSU vesting is the standard top-performer pattern — the first lender just didn’t know how to read pharma/device W-2 multi-component structure with proper B3-3.1-09 RSU analysis.

44-day close · Weston, FL

Talk to a pharma/device sales mortgage specialist

Get a pharma or medical device sales mortgage from a lender who reads W-2 base + commission, quota accelerator structure, President’s Club bonus, RSU stock compensation, quarterly spiff income, and sign-on/retention bonuses as one file.

No application. No credit pull. A 20-minute conversation where we look at your W-2 base + commission + bonus structure at Pfizer, Merck, J&J, BMS, AbbVie, Lilly, AstraZeneca, Novartis, Roche, GSK, Sanofi, Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Smith+Nephew, Abbott, Edwards Lifesciences, Intuitive Surgical, or BD, your quota and accelerator commission structure, your President’s Club bonus qualification history, your RSU stock compensation from LTIP grants with continuing vesting schedule, your quarterly spiff bonus history, any active sign-on or retention bonus structures with remaining vesting, your auto allowance, and any district/regional sales management or strategic account manager components — then we tell you whether Conventional Conforming W-2, Conventional Jumbo, Conventional Jumbo with RSU equity, or Asset-Depletion Non-QM fits best and roughly what the numbers look like. If we’re not the right shop, we’ll tell you that too.

Talk to Our Team Back to the sales professionals hub

Jim Blackburn NMLS #1072866 · Stairway Mortgage

Key facts every pharma or medical device sales rep should know before applying for a mortgage.

Pharma & medical device sales mortgage solutions for every career stage.

New rep (Years 1–2)

Established pharma rep

Established medical device rep

Top performer / President’s Club consistent

District/Regional sales manager

How we calculate qualifying income for your pharma or medical device sales mortgage.

Method 1 — W-2 base + commission + quarterly bonus + President’s Club (the rep default)

Method 2 — W-2 + RSU stock compensation aggregation (the high-tier method)

Method 3 — Multi-year sign-on / retention bonus structures (the transition method)

Method 4 — District/regional sales manager (multi-component W-2)

The income most lenders refuse to count on a pharma or medical device sales file.

Quota-based accelerator commission structure

President’s Club bonus (top 10-15% of reps)

RSU stock compensation from LTIP grants

Quarterly spiff and SPIF promotional bonuses

Auto allowance and vehicle/fuel programs

Sign-on and retention bonus structures with vesting

Which loan program fits your pharma or medical device sales mortgage situation.

Conventional Conforming W-2 (primary)

Conventional Jumbo (top performer)

Conventional Jumbo + RSU equity

Multi-source (W-2 + RSU + bonus)

Asset-Depletion Non-QM (post-IPO/stock liquidity)

Bank Statement Program Non-QM (rare)

FHA Conventional Alternative

The pharma/device sales mortgage in context: 6 forces shaping how reps qualify.

Force 1 — Pharma industry consolidation and biosimilar competition

Force 2 — IRA drug pricing reform (2022)

Force 3 — GLP-1 boom reshaping pharma sales territories

Force 4 — Medical device consolidation through M&A

Force 5 — Hospital and IDN consolidation

Force 6 — Robotic surgery growth (Intuitive Surgical, Stryker Mako)

Pharma & medical device sales mortgage by career stage.

New rep

Established pharma or medical device rep

Top performer / President’s Club consistent

District/regional manager or strategic account manager

What pharma and medical device sales reps say about their Stairway mortgage.

Pharma and medical device sales mortgage questions, answered.

More on pharma/device sales mortgages, W-2 multi-component aggregation, and RSU vesting analysis.

Other sales paths

Loan-program details

Calculators & tools

Sources & further reading.

PhRMA / AdvaMed & pharma/device industry

IRS & tax guidance

Cornell Law — statutory references

Mortgage program & underwriting guidelines

BLS & legislation

Pharma/device sales mortgage, structured right.

Get a pharma or medical device sales mortgage from a lender who reads W-2 base + commission, quota accelerator structure, President’s Club bonus, RSU stock compensation, quarterly spiff income, and sign-on/retention bonuses as one file.

Download The Stairway Roadmap.